1. < Home

OMERACT

Core domain set for chronic and/or recurrent manifestations of calcium pyrophosphate deposition disease: OMERACT delphi survey to establish consensus

Zhang Y, Tedeschi SK, Abhishek A, Hensey O, Grossberg D, Cai K, Shea B, Singh JA, Christensen R, Serban T, Cipolletta E, Parperis K, Diaz-Torne[...]

By sjmartinez • March 15, 2025
Core domain set for studies of acute calcium pyrophosphate crystal arthritis: OMERACT delphi survey to establish consensus

Zhang Y, Tedeschi SK, Abhishek A, Hensey O, Grossberg D, Cai K, Shea B, Singh JA, Christensen R, Serban T, Cipolletta E, Parperis K, Diaz-Torne[...]

By sjmartinez • March 5, 2025
Stakeholder endorsement advancing the implementation of a patient-reported domain for harms in rheumatology clinical trials: Outcome of the OMERACT Safety Working Group

Berthelsen DB, Simon LS, Ioannidis JPA, Voshaar M, Richards P, Goel N, Strand V, Nielsen SM, Shea BJ, Tugwell P, Bartlett SJ, Hazlewood GS, March[...]

By sjmartinez • November 3, 2023